leadf
logo-loader
viewAgios Pharmaceuticals

Agios says adios to some investors as cash seen shrinking

Shares of Agios Pharmaceuticals lose 13% after the company reports disappointing full-year results and a sapped cash outlook

6862528051_212f743008_o_opt_opt_opt.jpg
Cash seen slipping in 2016

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) lost 13% on Thursday after the company reported disappointing full-year results and a sapped cash outlook.

Agios, a leader in the fields of cancer metabolism and rare genetic metabolic disorders, reported a net loss for the year ended December 31, 2015 was $117.7mln, compared to a net loss of $53.5mln for the previous same period.

Agios works closely with biotech company Celgene (NASDAQ:CELG) as a collaboration partner. But revenues from such collaboration fell to  $59.1mln for the year ended December 31, 2015, compared with $65.4mln a year earlier.

Beginning in the first quarter of 2015, the company began offsetting research and development expense for amounts received from Celgene for reimbursement of certain development costs incurred on Celgene’s behalf related to AG-221 which were presented as gross collaboration revenue during 2014.

Research and development expenses shot up, and were $141.8mln, including $17.4mln of stock-based compensation expenses, compared to $100.4mln, including $6.7mln in stock-based compensation expenses, in 2014.

Although cash, cash equivalents and marketable securities were $375.9mln at the end of 2015, versus $467.4mln a year earlier, Agios said it expects to end 2016 with a further drop in the cash pile to around $180mln.

Agios shares were last seen down 13.4% at $36.32.

Quick facts: Agios Pharmaceuticals

Price: 46.57 USD

NASDAQ:AGIO
Market: NASDAQ
Market Cap: $3.23 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Victory Square Technologies sign LOI to acquire Hydreight, an on-demand and...

Victory Square Technologies (CSE: VST- OTC: VSQTF) Vahid Shababi joined Steve Darling from Proactive with news the company has signed a Letter of Intent to acquire Hydreight, which is a mobile health and wellness service provider operating in the United States. Shababi shares with Proactive...

25 minutes ago

2 min read